{"id":832875,"date":"2025-04-02T08:36:08","date_gmt":"2025-04-02T12:36:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/"},"modified":"2025-04-02T08:36:08","modified_gmt":"2025-04-02T12:36:08","slug":"revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/","title":{"rendered":"Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test<\/b><\/p>\n<p class=\"bwalignc\"><i>FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases<\/i><\/p>\n<p>WALTHAM, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.revvity.com&amp;esheet=54231951&amp;newsitemid=20250402936376&amp;lan=en-US&amp;anchor=Revvity%2C+Inc.&amp;index=1&amp;md5=904ee903513b4887a036397ca29223b9\">Revvity, Inc.<\/a> (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finfo.revvity.com%2FT-SPOT-AP2400&amp;esheet=54231951&amp;newsitemid=20250402936376&amp;lan=en-US&amp;anchor=Auto-Pure+2400+liquid+handling+platform+with+the+T-SPOT%26%238482%3B.TB+test&amp;index=2&amp;md5=7f4bbd4994a5ea0f703edcfe9b755969\">Auto-Pure 2400 liquid handling platform with the T-SPOT\u2122.TB test<\/a>. Initially <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.revvity.com%2Fpress-announcements%2Fpress-releases%2Fpress-release-details%2F2024%2FRevvity-Unveils-a-New-Era-of-Automated-Tuberculosis-Testing%2Fdefault.aspx&amp;esheet=54231951&amp;newsitemid=20250402936376&amp;lan=en-US&amp;anchor=launched&amp;index=3&amp;md5=b20f821f9c0b67380c68a3cb4c53bcec\">launched<\/a> outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-throughput solution delivering accurate diagnostic results to support timely treatment and containment in the U.S. as well as other locations around the world.\n<\/p>\n<p>\n\u201cThe integration of the Auto-Pure 2400 platform with the T-SPOT.TB test gives laboratories the ability to process latent TB tests at higher volumes without compromising clinical accuracy,\u201d said Yves Dubaquie, senior vice president, diagnostics at Revvity. \u201cBy automating T-SPOT.TB testing, we are empowering laboratories with increased throughput and reliability, ultimately leading to better patient outcomes.\u201d\n<\/p>\n<p><b>Key Features of the Automated Latent Tuberculosis Test<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe Auto-Pure 2400 system seamlessly integrates liquid handling and magnetic cell isolation technology.\n<\/li>\n<li>\nThe Auto-Pure 2400 system streamlines lab workflows, testing up to 24 samples per run, completing Day 1 of the T-SPOT.TB testing in under 3.5 hours with only a single mid-run user interaction.\n<\/li>\n<li>\nThe WHO identifies T-SPOT.TB as the only ELISPOT-based IGRA. This methodology, with its added cell number normalization step, ensures reproducible results by minimizing the impact of pre-analytical variables seen in other IGRAs.\n<\/li>\n<li>\nThe T-SPOT.TB test delivers key advantages, including <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F29523321%2F&amp;esheet=54231951&amp;newsitemid=20250402936376&amp;lan=en-US&amp;anchor=fewer+indeterminate+results%2C+reduced+need+for+repeat+testing&amp;index=4&amp;md5=514a904f231cb7adfe19a6e11b696447\">fewer indeterminate results, reduced need for repeat testing<\/a>, and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F20823644%2F&amp;esheet=54231951&amp;newsitemid=20250402936376&amp;lan=en-US&amp;anchor=consistent+performance+in+immunocompromised+patients&amp;index=5&amp;md5=97ed0850436457139230f1607acb74fd\">consistent performance in immunocompromised patients<\/a>.\n<\/li>\n<\/ul>\n<p><i>For In Vitro Diagnostic Use. Products may not be licensed in accordance with the laws in all countries. Please check with your local representative for availability.<\/i><\/p>\n<p><b>About Revvity<\/b><\/p>\n<p>\nAt Revvity, we turn &#8220;impossible&#8221; into innovation and transform scientific challenges into breakthroughs. We deliver cutting-edge solutions in diagnostics, translational multi-omics, biomarker discovery, imaging, screening, and informatics\u2014helping our customers move from research to real-world impact.\n<\/p>\n<p>\nWith 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&amp;P 500 index and has customers in more than 160 countries.\n<\/p>\n<p>\nStay updated by following our <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fnews.revvity.com%2F&amp;esheet=54231951&amp;newsitemid=20250402936376&amp;lan=en-US&amp;anchor=Newsroom&amp;index=6&amp;md5=afa9edff026fe32c38b0e14bc02d5176\">Newsroom<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Frevvity%2F&amp;esheet=54231951&amp;newsitemid=20250402936376&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=2411f97f2f136f965fb489edc3e92987\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FRevvityInc&amp;esheet=54231951&amp;newsitemid=20250402936376&amp;lan=en-US&amp;anchor=X&amp;index=8&amp;md5=ba72a68425f0a366878a629b669cef90\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUCUqLrqOpUUwhz3UaLn78tVQ&amp;esheet=54231951&amp;newsitemid=20250402936376&amp;lan=en-US&amp;anchor=YouTube&amp;index=9&amp;md5=3ce0c69592816ca8245014dd3b24c981\">YouTube<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FRevvityInc&amp;esheet=54231951&amp;newsitemid=20250402936376&amp;lan=en-US&amp;anchor=Facebook&amp;index=10&amp;md5=763d2204ecc5c203e20254272928c9ca\">Facebook<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Frevvity%2F&amp;esheet=54231951&amp;newsitemid=20250402936376&amp;lan=en-US&amp;anchor=Instagram&amp;index=11&amp;md5=0b8faf73cf9013d81d1a5e9eef3e8dd4\">Instagram<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250402936376r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250402936376\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250402936376\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations:<br \/>\n<\/b><br \/>Steve Willoughby<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:steve.willoughby@revvity.com\">steve.willoughby@revvity.com<br \/>\n<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Chet Murray<br \/>\n<br \/>(781) 462-5126<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:chet.murray@revvity.com\">chet.murray@revvity.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Public Policy Other Policy Issues Children Packaging Baby\/Maternity Engineering Manufacturing Other Health Congressional News\/Views Public Policy\/Government Software Other Science Research Pharmaceutical Hardware Healthcare Reform Medical Devices Infectious Diseases Consumer Electronics Technology Science Biotechnology Health General Health FDA Consumer<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250402936376\/en\/2427060\/3\/rev_logo_rgb_black.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT\u2122.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-throughput solution delivering accurate diagnostic results to support timely treatment and containment in the U.S. as well as other locations around the world. \u201cThe integration of the Auto-Pure &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-832875","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT\u2122.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-throughput solution delivering accurate diagnostic results to support timely treatment and containment in the U.S. as well as other locations around the world. \u201cThe integration of the Auto-Pure &hellip; Continue reading &quot;Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-02T12:36:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250402936376r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test\",\"datePublished\":\"2025-04-02T12:36:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\\\/\"},\"wordCount\":484,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250402936376r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\\\/\",\"name\":\"Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250402936376r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-04-02T12:36:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250402936376r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250402936376r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/","og_locale":"en_US","og_type":"article","og_title":"Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - Market Newsdesk","og_description":"Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT\u2122.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-throughput solution delivering accurate diagnostic results to support timely treatment and containment in the U.S. as well as other locations around the world. \u201cThe integration of the Auto-Pure &hellip; Continue reading \"Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-02T12:36:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250402936376r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test","datePublished":"2025-04-02T12:36:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/"},"wordCount":484,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250402936376r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/","name":"Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250402936376r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-04-02T12:36:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250402936376r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250402936376r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revvity-secures-fda-approval-for-improved-automated-latent-tuberculosis-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=832875"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832875\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=832875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=832875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=832875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}